A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.
about
Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosisPharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitorApplication of modeling and simulation to a long-term clinical trial: a direct comparison of simulated data and data actually observed in Japanese osteoporosis patients following 3-year ibandronate treatment.Romiplostim dose response in patients with immune thrombocytopenia.A network modeling approach for the spatial distribution and structure of bone mineral contentIdentification of the mechanism of action of a glucokinase activator from oral glucose tolerance test data in type 2 diabetic patients based on an integrated glucose-insulin model.Assessment of a bone biopsy technique for measuring tiludronate in horses: a preliminary study.Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women.HIF targets in bone remodeling and metastatic disease.The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties.Romiplostim dose-response in patients with myelodysplastic syndromesModeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats.Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders.A systematic review and empirical analysis of the relation between dose and duration of drug action.Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).Ibandronate: A Review in Japanese Patients with Osteoporosis.A semi-mechanistic model of bone mineral density and bone turnover based on a circular model of bone remodeling.Analysis of clinical trials with biologics using dose-time-response models.Dissociated Agonist of Glucocorticoid Receptor or Prednisone for Active Rheumatoid Arthritis: Effects on P1NP and Osteocalcin PharmacodynamicsBasic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methodsOptimal design of clinical trials with biologics using dose-time-response models.Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females.Modelling the dose-response relationship: the fair share of pharmacokinetic and pharmacodynamic information.
P2860
Q24680238-55572062-3FBC-482B-ABDF-7C61AEB87A2FQ28270421-8D54240C-90FF-4B15-AE8E-0F31BCCD8D38Q30870287-F450F1E6-536D-4217-B0F5-3C687BBA90AEQ33398730-82357826-088C-4B87-81B8-20DC5901285CQ33574150-8FE9A70C-C9FA-49FE-8A89-2AA408C3BADDQ34102632-B7156968-0FCD-4044-ABBC-F6CA1BE0CE2DQ34711063-4098B39A-A97F-4F70-9A22-10B40DE399D5Q35449502-27339FA5-661C-46C4-88F5-57EA71D1D920Q35554344-3DAB3923-FA62-488D-A4DC-BEEE7E6D0AECQ36761569-74CEE30F-F3ED-4D40-910B-BFEEEA665905Q36948110-264DBB94-4470-4C0E-8396-4A9B8A9164CEQ36952913-AB6411BD-D057-4BCE-A777-1A47C72D0AD9Q37430269-FC6B2EDC-F46F-4A08-A7FB-5E96E6774937Q37606934-B04E9C4F-0B47-4910-B9CC-F2084623D700Q37886138-24091DFC-C540-49D6-815C-911429ED4CA4Q38722948-6106E7EB-0795-4F4A-A213-0EB57B5E1772Q38750001-14EACEAB-877B-4208-8AF4-AA32C84241C4Q40783785-1B8AFEB5-8017-4FBB-B07A-5D9FD71E26B2Q40852651-6275E603-C15F-45FE-9C94-F7C2243981E7Q41142504-D23ECEAA-0EBE-451B-8AB8-89B33BAAE9E5Q41775229-E4795197-1997-4025-A190-F1D8CDDA0F69Q51039918-E97940C6-C2A5-4E90-BD2F-A5BC07B2F0CCQ51152617-8C9BF626-A14F-49D0-B7D8-58B944B67B2CQ53229062-538946E5-826B-4BC0-8806-E8246F956576
P2860
A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
A semimechanistic and mechanis ...... the treatment of osteoporosis.
@ast
A semimechanistic and mechanis ...... the treatment of osteoporosis.
@en
type
label
A semimechanistic and mechanis ...... the treatment of osteoporosis.
@ast
A semimechanistic and mechanis ...... the treatment of osteoporosis.
@en
prefLabel
A semimechanistic and mechanis ...... the treatment of osteoporosis.
@ast
A semimechanistic and mechanis ...... the treatment of osteoporosis.
@en
P2093
P2860
P1476
A semimechanistic and mechanis ...... the treatment of osteoporosis.
@en
P2093
Goonaseelan Pillai
Jean-Louis Steimer
Philippe Jacqmin
Ralph C Schimmer
Ronald Gieschke
Timothy Goggin
P2860
P304
P356
10.1111/J.1365-2125.2004.02224.X
P407
P577
2004-12-01T00:00:00Z